
|Articles|July 28, 2015
Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Advertisement
Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves TTFields Device With Chemo in Pancreatic Cancer
2
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers
3
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
4
FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer
5




































